

## Notice of Preliminary Hearing on Statement of Scope

The Controlled Substances Board announces that it will hold a preliminary public hearing on Statement of Scope SS 111-19 for amending CSB 4 relating to designating Gabapentin as a monitored drug. The type of the proposed rule is permanent. In accordance with s. 227.136, Stats., the Controlled Substances Board is seeking public comment and feedback on Statement of Scope SS 111-19, at the time and place shown below.

### Hearing Information

Date: January 10, 2020  
Time: 9:30 a.m.  
Location: 4822 Madison Yards Way, Room N208  
Madison, Wisconsin

### Appearances at the Hearing and Submittal of Written Comments

Persons wishing to provide oral or written comments regarding the Statement of Scope for the proposed administrative rule may appear during the hearing.

Comments may be submitted to Sharon Henes, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, P.O. Box 8366, Madison Wisconsin 53708-8366 or by email to [DSPSAdminRules@wisconsin.gov](mailto:DSPSAdminRules@wisconsin.gov).


The Statement of Scope may be reviewed and comments made at [https://docs.legis.wisconsin.gov/code/scope\\_statements/comment](https://docs.legis.wisconsin.gov/code/scope_statements/comment).

Comments must be received at or before the public hearing.

### Agency Contact Person

Sharon Henes, [DSPSAdminRules@wisconsin.gov](mailto:DSPSAdminRules@wisconsin.gov), (608) 261-2377

This Notice of Preliminary Hearing on Statement of Scope is approved by:



Member of the Board  
Pharmacy Examining Board

November 15, 2019  
Date